Tizanidine
Product Images NDC 67296-1192

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-1192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Tizanidine 67296 1192)

Label for Tizanidine HCl 4 mg tablets by RedPharm Drug, Inc., containing 15 tablets. Includes NDC number 67296-1192 and information on lot number H19001X1 and expiration date 12/20. The label indicates Rx only status and storage instructions at controlled room temperature. Manufactured by Unichem Laboratories Ltd in India and distributed by Redpharm Drug in Eden Prairie, MN.*

FDA Label Image

Molecular Structure (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 01)

Chemical structure of Tizanidine hydrochloride, showing its molecular framework including a chlorine atom, nitrogen and sulfur heterocycles, and a piperazine ring.*

FDA Label Image

Figure-1 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 02)

A line chart showing plasma tizanidine concentration (ng/mL) versus hours from dosing up to 24 hours. It compares four curves representing 4 mg tizanidine tablets and capsules, both with and without food.*

FDA Label Image

Figure 3 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 03)

A line graph depicting improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, while the x-axis shows hours post-dose. Error bars indicate variability at each time point.*

FDA Label Image

Figure 4 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 04)

A line graph comparing improvement in Ashworth Scores over three time points: end of titration (Week 3), end of maintenance (Week 7), and endpoint (last observation carried forward). The graph shows two groups: tizanidine (mean dose 28.8 mg) with squares indicating greater improvement, and placebo with circles showing less improvement. Error bars represent variability for each data point.*

FDA Label Image

Logo (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.